The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 14, Issue 1, 2004, Pages 51-56

  Ayhan, A ^a,a   Al, R A ^a   Baykal, Cem ^a,b   Demirtas, E ^a   Yuce K ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Cytoreductive surgery; Ovarian carcinoma; Splenectomy; Survival

Indexed keywords

ABDOMINAL BLEEDING; ADULT; ADVANCED CANCER; AGED; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; ENTEROCUTANEOUS FISTULA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; ILEUS; LUNG EMBOLISM; LYMPH NODE DISSECTION; METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PARAAORTIC LYMPH NODE; PATIENT SELECTION; PERITONITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SPLEEN; SPLEEN METASTASIS; SPLENECTOMY; STATISTICAL ANALYSIS; SURGICAL INFECTION;

CARCINOMA; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; TURKEY;

EID: 1442274996     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014940.x     Document Type: Review

References (33)

1. Joyeux H, Szawlowski AW, Saint-Aubert B, Elazhary MM, Solassol C, Pujol H. Aggressive regional surgery for advanced ovarian carcinoma. Cancer 1986;57:142-7.
2. Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol 1999;72:407-10.
3. Scarabelli C, Gallo A, Campagnutta E, Carbone A. Splenectomy dyring primary and secondary cytoreductive surgery for epithelial ovarian cancer. Int J Gynecol Cancer 1998;8:215-21.
4. Sonnendecker EW, Guidozzi F, Margolius KA. Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1989;35:301-6.
5. Morris M, Gershenson DM, Burke TW, Wharton JT, Copeland LJ, Rutledge FN. Splenectomy in gynecologic oncology, indications, complications, and technique. Gynecol Oncol 1991;43:118-22.
6. Chen LM, Leuchter RS, Lagasse LD, Karlan BY. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000;77:362-8.
7. Eichner ER. Splenic function: normal, too much and too little. Am J Med 1979;66:311-20.
8. Heintz APM, Berek JS. Cytoreductive surgery for ovarian carcinoma. In: Piver, MS, ed. Ovarian Malignancies: Diagnostic and Therapeutic Advances. Edinburgh; New York: Churchill Livingstone 1987, 129-43.
9. Gershenson DM. Primary cytoreduction for advanced epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994;21:121-40.
10. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994;53:326-30.
11. Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989;64:1508-13.
12. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-11.
13. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
14. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer, how much and when. Gynecol Oncol 1991;40:195-200.
15. Goodman HM, Harlow BL, Sheets EE et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992;46:367-71.
16. Bonnefoi H, A'Hern RP, Fisher C et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-75.
17. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
18. Berek JS, Fu YS, Hacker NF. Ovarian cancer. In: Berek, JS, Adashi, EY, Hillard, PA, Jones, HW, eds. Novak's Gynecology. 12th edn. Baltimore: Williams & Wilkins 1996, 1155-230.
19. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994;74:656-63.
20. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-8.
21. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
22. Del Campo JM, Felip E, Rubio D et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994;53:27-32.
23. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
24. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
25. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-87.
26. Munkarah AR, Hallum AV, Morris M et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7.
27. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171-5.
28. Blythe JG, Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecol Oncol 1982;14:396-408.
29. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 1985;20:190-5.
30. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
31. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-5.
32. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 1993;5:198-202.
33. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.